NCT01813344

Brief Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 13, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 19, 2013

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Last Updated

March 19, 2013

Status Verified

March 1, 2013

Enrollment Period

1.4 years

First QC Date

March 13, 2013

Last Update Submit

March 14, 2013

Conditions

Lymphoblastic Lymphoma

Keywords

Adult lymphoblastic lymphomaHyper-CVADfirst-line treatment

Outcome Measures

Primary Outcomes (2)

  • Overall survival

    3-year

  • Progression free survival

    3-year

Secondary Outcomes (1)

  • Response Rate

    24 weeks

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult lymphoblast lymphoma patients treated with hyper-CVAD regimen in Korea

You may qualify if:

  • age over 18 at diagnosis
  • Pathologically proven lymphoblastic lymphoma

You may not qualify if:

  • proven HIV infection
  • pretreatment with other regimens

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ajou Universtiy School of Medicine

Suwon, Kyeonggi, 443-721, South Korea

RECRUITING

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Seong Hyun Jeong, MD

CONTACT

+82-31-219-5989seonghyunmd@naver.com

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

March 13, 2013

First Posted

March 19, 2013

Study Start

January 1, 2012

Primary Completion

June 1, 2013

Last Updated

March 19, 2013

Record last verified: 2013-03

Locations

KR(1)